Cargando…
Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
Multi‐targeted agents represent the next generation of targeted therapies for solid tumors, and patients with acquired resistance to EGFR‐tyrosine kinase inhibitors (TKIs) may also benefit from their combination with TKI therapy. Third‐generation targeted drugs, such as osimertinib, are very expensi...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928351/ https://www.ncbi.nlm.nih.gov/pubmed/29575765 http://dx.doi.org/10.1111/1759-7714.12624 |